XML 49 R32.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail) |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Oct. 03, 2018 USD ($) Obligation | Nov. 30, 2018 USD ($) | Oct. 31, 2018 USD ($) Target $ / shares shares | Sep. 30, 2018 USD ($) $ / shares | Sep. 30, 2017 USD ($) | Sep. 30, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Stock issued, price per share | $ / shares |  |  |  | $ 5.25 |  |
Proceeds from the issuance of common stock |  |  |  | $ 56,585,035 | $ 12,419,119 | $ 52,231,433
Collaboration and License agreements | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Cash received as due under collaboration agreement | $ 197,800,000 |  |  |  |  |
Initial transaction price | $ 197,800,000 |  |  |  |  |
Janssen | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Number of distinct performance obligations | Obligation | 1 |  |  |  |  |
Janssen | Common Stock Purchase Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Agreement date | Oct. 03, 2018 |  |  |  |  |
Janssen | License Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Agreement date | Oct. 03, 2018 |  |  |  |  |
Janssen | License Agreement | Maximum | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Development, regulatory and sales milestones payments |  |  | $ 1,600,000,000 |  |  |
Janssen | Research Collaboration and Option Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Agreement date | Oct. 03, 2018 |  |  |  |  |
Janssen | Collaboration Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Number of additional targets for development, regulatory and sales milestone payments | Target |  |  | 3 |  |  |
Janssen | Collaboration Agreement | Maximum | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Development, regulatory and sales milestones payments |  |  | $ 1,900,000,000 |  |  |
Janssen Pharmaceuticals Inc | Common Stock Purchase Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Agreement date | Oct. 03, 2018 |  |  |  |  |
Janssen Pharmaceuticals Inc | Research Collaboration and Option Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Agreement date | Oct. 03, 2018 |  |  |  |  |
JJDC | Common Stock Purchase Agreement | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Shares issued | shares |  |  | 3,260,869 |  |  |
Stock issued, price per share | $ / shares |  |  | $ 23.00 |  |  |
Proceeds from the issuance of common stock |  |  | $ 75,000,000 |  |  |
JJDC | Collaboration and License agreements | Subsequent Event |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Cash received as due under collaboration agreement |  | $ 175,000,000 | 175,000,000 |  |  |
Proceeds from the issuance of common stock |  |  | $ 75,000,000 |  |  |

X
- Definition Agreement date. + References No definition available. + Details
Name: | arwr_AgreementDate
Namespace Prefix: | arwr_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received as due under collaboration agreement. + References No definition available. + Details
Name: | arwr_CashReceivedAsDueUnderCollaborationAgreement
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development regulatory and sales milestones payments. + References No definition available. + Details
Name: | arwr_DevelopmentRegulatoryAndSalesMilestonesPayments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Initial transaction price. + References No definition available. + Details
Name: | arwr_InitialTransactionPrice
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of additional targets for development, regulatory and sales milestone payments. + References No definition available. + Details
Name: | arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of distinct performance obligations. + References No definition available. + Details
Name: | arwr_NumberOfDistinctPerformanceObligations
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=arwr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_ResearchCollaborationAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |